text: Subject disposition.
  Data from 110 enrolled subjects were eligible for analysis. The demographics of the study subjects, by site, are recorded in Table 1. The population studied was predominantly not HIV infected (92%), and by the study entry criteria, their probability of infection was considered to be low. The risk categories assigned at the time of study entry were combined into groups for analysis, based on the predisposition for PCP. The analysis groups were as follows: (i) HIV/AIDS, (ii) lung transplant (one subject with a dual organ transplant [lung/kidney] was included in this category), (iii) all other organ transplants and allogeneic hematopoietic stem cell transplants (HSCT), (iv) leukemia, other hematological disorders, and autologous HSCT, (v) other solid tumors, and (vi) other nonmalignant conditions.
  Table 1.
  Subject enrollment, disposition, and demographics by sitea
  Characteristic Valueb
  Site 1 Site 2 Site 3 Site 4
  Enrollment
  Unique subjects 18 29 22 62
  Subjects entering into primary analysisc 18 22 22 48
  Subjects with repeat visits 0 0 0 16
  No. of samples assayed 18 22 22 70
  Gender
  Male 7 10 13 29
  Female 11 12 9 19
  Race
  Caucasian 12 4 0 48
  Black 6 13 0 0
  Other (nonwhite) 0 5 0 0
  No data 0 0 22 0
  Mean (range) age (yr) 57 (26-78) 54 (21-75) 52 (26-74) 56 (23-73)
  Pretest probability of PCP
  Moderate 0 3 4 0
  Low 18 19 18 48
  Sample type
  BAL 18 20 20 43
  Sputum 0 1 1 0
  Other LRT 0 1 1 5
  At-risk group
  HIV/AIDS 0 3 6 0
  Lung transplant 8 0 1 31
  Other transplants 1 7 3 0
  Leukemia 1 1 7 0
  Other solid tumors 2 1 1 7
  Other nonmalignant conditions 6 10 4 10
  a
  The testing and enrollment sites for the study were Duke University School of Medicine, Durham, NC; Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY; Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland; and Medizinische Universitat and Landeskrankenhaus Natters, Innsbruck, Austria.
  b
  Except where otherwise indicated, values are numbers of patients.
  c
  Subjects were excluded from analysis if they withdrew consent or if there was inadequate sample left for PCR testing.
  
entities.text: ['lung']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T1
entities.text: ['organ']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T2
entities.text: ['lung']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T3
entities.text: ['kidney']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T4
entities.text: ['organ']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T5
entities.text: ['allogeneic hematopoietic stem cell']
entities.type: Cell
entities.entity_id: PMC-3122670-sec-13_T6
entities.text: ['solid tumors']
entities.type: Pathological_formation
entities.entity_id: PMC-3122670-sec-13_T7
entities.text: ['Sputum']
entities.type: Organism_substance
entities.entity_id: PMC-3122670-sec-13_T8
entities.text: ['Lung']
entities.type: Organ
entities.entity_id: PMC-3122670-sec-13_T9
entities.text: ['solid tumors']
entities.type: Pathological_formation
entities.entity_id: PMC-3122670-sec-13_T10